MONTREAL--(BUSINESS WIRE)--Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, announced today that it received notice of a Decision to Grant on an important composition of matter patent from the Japanese Patent Office. This decision covers Application No. 2012-193673, entitled “Tdf-related compounds and analogs thereof.” This patent provides coverage for Thrasos’ lead product THR-184, currently in Phase 2 clinical testing for the prevention of acute kidney injury (AKI) in patients undergoing cardiac surgery. The Company’s 452 patient Phase 2 trial has completed enrollment and data is expected in early 2016.
“The patent that will issue from Application No. 2012-193673 builds on the extensive intellectual property protection we already have in place by expanding geographic coverage and patent life,” said Richard Andrews President and CEO of Thrasos Therapeutics. “Comprehensive patent protection is an important part of our corporate strategy, and we are pleased this patent has been allowed by the Japanese Patent Office. The timing of this grant is particularly important as we are eagerly awaiting results from our Phase 2 AKI study, which we are hoping to announce early next year.”
Thrasos has received patent protection for THR-184 in the United States, Australia and a large number of countries in Europe including England, France, Germany, Italy, and Spain. This patent covers a genus of polypeptides, including THR-184, and the use of these peptides to treat subjects having, for example, kidney disease. The allowed claims also cover nucleic acids, vectors and cells comprising the nucleic acids that encode the allowed peptides.
THR-184 is a proprietary peptide that acts on the BMP/Smad pathway. Results from a broad set of preclinical studies showed THR-184 had protective effects in animal models of AKI, and in two Phase 1 clinical trials THR-184 was found to be safe and well-tolerated. THR-184 has been granted Fast Track designation for the prevention of AKI following cardiac surgery by the U.S. Food and Drug Administration (FDA). Enrollment has been completed for the study, with data expected in early 2016.
Thrasos is a privately held, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company’s lead compound, THR-184, is currently being evaluated in a Phase 2 clinical study for the prevention of Acute Kidney Injury (AKI) in patients undergoing cardiac surgery. The company believes that its technology will be broadly applicable to other types of major surgery where AKI is also a significant complication. In addition, Thrasos is developing compounds for Chronic Kidney Disease, which can result in permanent loss of kidney function and the need for dialysis. The Company is headquartered in Montreal, Canada, with a satellite office in Boston, Massachusetts. www.thrasos.com